The Short-term Effect of Immunomodulatory Treatment With Interferon Beta-1b (Betaferon) on Fatigue and Depression in First-time Treated Patients With Relapsing-remitting Multiple Sclerosis.
Phase of Trial: Phase IV
Latest Information Update: 23 Jan 2015
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms FADO
- Sponsors Bayer
- 01 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 19 May 2011 New trial record